Two synthetic VIP receptor antagonists, including one based on a GHRH analog, were shown to competitively inhibit VIP binding and block VIP-stimulated signaling in both rat and mouse macrophages. The antagonists specifically targeted VIP receptors without affecting other receptor pathways, and cross-linking experiments confirmed reduced receptor complex formation, validating these compounds as selective tools for studying VIP's role in immune cell function.
Pozo, D; Montilla, M L; Guerrero, J M; Calvo, J R